| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | 80.898 | 113.123 | 132.126 | 188.877 | 231.199 | 5.963 | 27.430 |
| Total Income - EUR | - | - | - | 84.159 | 113.123 | 142.733 | 210.649 | 237.260 | 5.963 | 31.526 |
| Total Expenses - EUR | - | - | - | 95.771 | 113.693 | 75.855 | 83.106 | 92.137 | 22.102 | 15.249 |
| Gross Profit/Loss - EUR | - | - | - | -11.612 | -570 | 66.878 | 127.543 | 145.123 | -16.139 | 16.276 |
| Net Profit/Loss - EUR | - | - | - | -12.555 | -1.701 | 65.558 | 125.480 | 142.960 | -16.139 | 13.672 |
| Employees | - | - | - | 3 | 3 | 3 | 3 | 3 | 0 | 0 |
Check the financial reports for the company - Lantaris Pharma Services S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | 0 | 0 | 0 | 0 | 2.779 | 1.874 | 1.767 |
| Current Assets | - | - | - | 6.646 | 7.348 | 58.453 | 132.090 | 144.859 | -2.392 | 2.943 |
| Inventories | - | - | - | 24 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | 0 | 228 | 45.275 | 122.973 | 142.794 | 651 | 1.055 |
| Cash | - | - | - | 6.622 | 7.120 | 13.178 | 9.118 | 2.065 | -3.043 | 1.887 |
| Shareholders Funds | - | - | - | -12.512 | -13.971 | 51.852 | 125.528 | 142.426 | -16.043 | -2.282 |
| Social Capital | - | - | - | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | 19.158 | 21.319 | 6.601 | 6.562 | 5.213 | 15.525 | 7.133 |
| Income in Advance | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7022 - 7022" | |||||||||
| CAEN Financial Year |
7022
|
|||||||||
Comments - Lantaris Pharma Services S.r.l.